Mo H - Search Results

1

Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.

Lawitz E, Yang JC, Stamm LM, Taylor JG, Cheng G, Brainard DM, Miller MD, Mo H, Dvory-Sobol H. Lawitz E, et al. Among authors: mo h. Antivir Ther. 2018;23(4):325-334. doi: 10.3851/IMP3202. Antivir Ther. 2018. PMID: 29063860 Clinical Trial.

2

Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.

Koev G, Dekhtyar T, Han L, Yan P, Ng TI, Lin CT, Mo H, Molla A. Koev G, et al. Among authors: mo h. Antiviral Res. 2007 Jan;73(1):78-83. doi: 10.1016/j.antiviral.2006.07.009. Epub 2006 Aug 17. Antiviral Res. 2007. PMID: 16945431

3

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.

Qi X, Bae A, Liu S, Yang H, Sun SC, Harris J, Delaney W, Miller M, Mo H. Qi X, et al. Among authors: mo h. Antiviral Res. 2009 Feb;81(2):166-73. doi: 10.1016/j.antiviral.2008.11.002. Epub 2008 Dec 6. Antiviral Res. 2009. PMID: 19063924

4

Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.

Mo H, Yang C, Wang K, Wang Y, Huang M, Murray B, Qi X, Sun SC, Deshpande M, Rhodes G, Miller MD. Mo H, et al. J Viral Hepat. 2011 May;18(5):338-48. doi: 10.1111/j.1365-2893.2010.01314.x. J Viral Hepat. 2011. PMID: 20456634

5

Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.

Bae A, Sun SC, Qi X, Chen X, Ku K, Worth A, Wong KA, Harris J, Miller MD, Mo H. Bae A, et al. Among authors: mo h. Antimicrob Agents Chemother. 2010 Dec;54(12):5288-97. doi: 10.1128/AAC.00777-10. Epub 2010 Sep 20. Antimicrob Agents Chemother. 2010. PMID: 20855726 Free PMC article.

6

Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naïve HCV patient isolates.

Sun SC, Bae A, Qi X, Harris J, Wong KA, Miller MD, Mo H. Sun SC, et al. Among authors: mo h. J Viral Hepat. 2011 Dec;18(12):861-70. doi: 10.1111/j.1365-2893.2010.01396.x. Epub 2010 Nov 25. J Viral Hepat. 2011. PMID: 21108698

7

Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples.

Bae AS, Ku KS, Miller MD, Mo H, Svarovskaia ES. Bae AS, et al. Among authors: mo h. J Clin Microbiol. 2011 Sep;49(9):3168-74. doi: 10.1128/JCM.00274-11. Epub 2011 Jun 29. J Clin Microbiol. 2011. PMID: 21715590 Free PMC article.

8

In vitro anti-hepatitis C virus (HCV) resistance selection and characterization.

Mo H. Mo H. Curr Protoc Pharmacol. 2011 Jun;Chapter 13:Unit 13B.5. doi: 10.1002/0471141755.ph13b05s53. Curr Protoc Pharmacol. 2011. PMID: 21935899

9

An adaptive mutation in NS2 is essential for efficient production of infectious 1b/2a chimeric hepatitis C virus in cell culture.

Chan K, Cheng G, Beran RK, Yang H, Appleby TC, Pokrovskii MV, Mo H, Zhong W, Delaney WE 4th. Chan K, et al. Among authors: mo h. Virology. 2012 Jan 20;422(2):224-34. doi: 10.1016/j.virol.2011.10.022. Epub 2011 Nov 17. Virology. 2012. PMID: 22099378 Free article.

10

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. Lawitz EJ, et al. Among authors: mo h. J Hepatol. 2012 Jul;57(1):24-31. doi: 10.1016/j.jhep.2011.12.029. Epub 2012 Feb 5. J Hepatol. 2012. PMID: 22314425 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,435 results

Search Page

Filters